Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CARA Cara Therapeutics		$15.19	$8.13 ▼ $19.08	$24.33M	0.41	22,224 shs	237,144 shs
IMUX Immunic	$0.82 -5.7%	$0.87	$0.56 ▼ $2.11	$80.89M	1.39	1.24 million shs	1.37 million shs
VIRI Virios Therapeutics	$4.80 +3.1%	$4.84	$0.13 ▼ $1.04	$92.34M	1.58	1.05 million shs	18,008 shs
VTGN VistaGen Therapeutics	$3.34 +3.4%	$2.66	$1.90 ▼ $3.59	$102.47M	0.4	259,959 shs	586,089 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CARA Cara Therapeutics	0.00%	0.00%	0.00%	0.00%	+24.71%
IMUX Immunic	+2.35%	-7.93%	-11.16%	+32.00%	-38.30%
VIRI Virios Therapeutics	-6.81%	-4.32%	-3.53%	-12.10%	+2,413.51%
VTGN VistaGen Therapeutics	+1.57%	+5.56%	+5.56%	+28.17%	-8.24%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CARA Cara Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IMUX Immunic	2.7028 of 5 stars	3.6	1.0	0.0	0.0	3.1	2.5	0.6
VIRI Virios Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VTGN VistaGen Therapeutics	1.2869 of 5 stars	0.0	4.0	0.0	0.0	2.7	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CARA Cara Therapeutics	0.00	N/A	N/A	N/A
IMUX Immunic	3.29	Buy	$7.50	816.87% Upside
VIRI Virios Therapeutics	2.00	Hold	$5.00	4.28% Upside
VTGN VistaGen Therapeutics	3.00	Buy	N/A	N/A

Current Analyst Ratings Breakdown

Latest CARA, VTGN, VIRI, and IMUX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/8/2025	IMUX Immunic	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/25/2025	IMUX Immunic	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/18/2025	VTGN VistaGen Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
6/5/2025	IMUX Immunic	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
5/29/2025	IMUX Immunic	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$17.00 ➝ $10.00

(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CARA Cara Therapeutics	$7.14M	0.00	N/A	N/A	$12.58 per share	0.00
IMUX Immunic	N/A	N/A	N/A	N/A	$0.34 per share	N/A
VIRI Virios Therapeutics	N/A	N/A	N/A	N/A	$0.20 per share	N/A
VTGN VistaGen Therapeutics	$490K	207.87	N/A	N/A	$1.85 per share	1.79

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CARA Cara Therapeutics	-$118.51M	-$21.01	N/A	N/A	N/A	-1,099.76%	-367.97%	-107.43%	N/A
IMUX Immunic	-$100.51M	-$1.23	N/A	N/A	N/A	N/A	-461.46%	-217.16%	11/6/2025 (Estimated)
VIRI Virios Therapeutics	-$5.30M	-$0.27	N/A	N/A	N/A	N/A	-130.33%	-115.00%	N/A
VTGN VistaGen Therapeutics	-$51.42M	-$1.78	N/A	N/A	N/A	-6,777.08%	-74.06%	-64.10%	11/6/2025 (Estimated)

Latest CARA, VTGN, VIRI, and IMUX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	IMUX Immunic	-$0.18	-$0.20	-$0.02	-$0.20	N/A	N/A
8/7/2025	Q1 2026	VTGN VistaGen Therapeutics	-$0.47	-$0.47	N/A	-$0.47	$0.22 million	$0.24 million
6/17/2025	Q4 2025	VTGN VistaGen Therapeutics	-$0.52	-$0.43	+$0.09	-$0.43	$0.18 million	($0.01) million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CARA Cara Therapeutics	N/A	N/A	N/A	N/A	N/A
IMUX Immunic	N/A	N/A	N/A	N/A	N/A
VIRI Virios Therapeutics	N/A	N/A	N/A	N/A	N/A
VTGN VistaGen Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CARA Cara Therapeutics	N/A	4.77	4.71
IMUX Immunic	N/A	2.19	2.19
VIRI Virios Therapeutics	N/A	7.27	7.27
VTGN VistaGen Therapeutics	N/A	5.98	5.98

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CARA Cara Therapeutics	44.66%
IMUX Immunic	51.82%
VIRI Virios Therapeutics	9.05%
VTGN VistaGen Therapeutics	78.39%

Insider Ownership

Company	Insider Ownership
CARA Cara Therapeutics	3.10%
IMUX Immunic	4.60%
VIRI Virios Therapeutics	12.20%
VTGN VistaGen Therapeutics	2.85%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CARA Cara Therapeutics	80	4.57 million	4.43 million	Optionable
IMUX Immunic	70	98.65 million	94.11 million	Optionable
VIRI Virios Therapeutics	5	19.26 million	16.91 million	Optionable
VTGN VistaGen Therapeutics	40	30.68 million	29.81 million	Optionable

CARA, VTGN, VIRI, and IMUX Headlines

Recent News About These Companies

Wall Street Zen Upgrades VistaGen Therapeutics (NASDAQ:VTGN) to Hold

August 19, 2025 | americanbankingnews.com

While institutions invested in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) benefited from last week's 11% gain, retail investors stood to gain the most

August 17, 2025 | finance.yahoo.com

VistaGen Therapeutics (NASDAQ:VTGN) Rating Increased to Hold at Wall Street Zen

August 17, 2025 | marketbeat.com

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q1 2026 Earnings Call Transcript

August 12, 2025 | msn.com

VistaGen Therapeutics (NASDAQ:VTGN) Releases Quarterly Earnings Results, Meets Estimates

August 10, 2025 | marketbeat.com

Vistagen Therapeutics Inc (VTGN) Q1 2026 Earnings Call Highlights: Advancing Key Trials Amid ...

August 8, 2025 | finance.yahoo.com

Vistagen Therapeutics, Inc. (VTGN) Q1 2026 Earnings Call Transcript

August 8, 2025 | seekingalpha.com

Q1 2026 Vistagen Therapeutics Inc Earnings Call Transcript

August 8, 2025 | gurufocus.com

Vistagen (VTGN) Q1 R&D Expense Jumps 54%

August 7, 2025 | fool.com

VistaGen Therapeutics, Inc. (VTGN) Reports Q1 Loss, Misses Revenue Estimates

August 7, 2025 | zacks.com

Vistagen Reports Fiscal Year 2026 First Quarter Financial Results and Corporate Update

August 7, 2025 | businesswire.com

VistaGen Therapeutics Q1 2026 Earnings Preview

August 6, 2025 | msn.com

VistaGen Therapeutics (VTGN) to Release Earnings on Thursday

August 2, 2025 | marketbeat.com

Vistagen to Present at the BTIG Virtual Biotechnology Conference

July 24, 2025 | businesswire.com

Vistagen Honored for Outstanding Workplace Culture and Mental Health Leadership

July 15, 2025 | businesswire.com

Vistagen Honored for Outstanding Workplace Culture and Mental Health Leadership

July 15, 2025 | businesswire.com

Stifel Maintains Buy on Vistagen Therapeutics, Inc. (VTGN) Despite PAL-4 Delay

July 3, 2025 | msn.com

VTGN Vistagen Therapeutics, Inc. - Seeking Alpha

June 27, 2025 | seekingalpha.com

Vistagen Appoints Elissa Cote as Chief Corporate Development Officer

June 25, 2025 | businesswire.com

Vistagen Therapeutics, Inc. (VTGN) - Yahoo Finance

June 24, 2025 | finance.yahoo.com

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q4 2025 Earnings Call Transcript

June 22, 2025 | insidermonkey.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CARA, VTGN, VIRI, and IMUX Company Descriptions

Cara Therapeutics NASDAQ:CARA

Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

Immunic NASDAQ:IMUX

$0.82 -0.05 (-5.75%)

Closing price 04:00 PM Eastern

Extended Trading

$0.82 0.00 (-0.37%)

As of 05:51 PM Eastern

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.

Virios Therapeutics NASDAQ:VIRI

$4.80 +0.15 (+3.12%)

As of 08/28/2025

Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, Inc. in July 2020. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.

VistaGen Therapeutics NASDAQ:VTGN

$3.34 +0.11 (+3.41%)

Closing price 04:00 PM Eastern

Extended Trading

$3.32 -0.01 (-0.45%)

As of 05:38 PM Eastern

Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time